Informations générales (source: ClinicalTrials.gov)
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study (LARENA)
Observational
ARCAGY/ GINECO GROUP (Voir sur ClinicalTrials)
août 2024
décembre 2024
20 septembre 2024
LARENA is a multicentric retrospective study (secondary use of data) of consecutive
patients prospectively registered in the lenvatinib plus pembrolizumab French early
access program (Temporary Authorisation for Use). The source of data will be the
patient's medical file. We will manually review all files of the participating centers.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Europeen Georges Pompidou | Claire GERVAIS | Contact (sur clinicalTrials) | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | Diana BELLO ROUFAI | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre CARIO-HPCA - 22190 - Plerin - France | Anne-Claire HARDY-BESSARD | Contact (sur clinicalTrials) | |||
| Centre Eugène Marquis - 35000 - Rennes - France | Marie AUVRAY | Contact (sur clinicalTrials) | |||
| Centre François Baclesse - 14000 - Caen - France | François CHERIFI | Contact (sur clinicalTrials) | |||
| Centre Georges François Leclerc - 77980 - Dijon - France | Jean-David FUMET | Contact (sur clinicalTrials) | |||
| Centre Jean Perrin - 63011 - Clermont-ferrand - France | Elsa KALBACHER | Contact (sur clinicalTrials) | |||
| Centre Léon Bérard - 69008 - Lyon - France | Brunhilde HANVIC | Contact (sur clinicalTrials) | |||
| CHU Jean Minjoz - 25000 - Besancon - France | Laura MANSI | Contact (sur clinicalTrials) | |||
| ICANS - 67033 - Strasbourg - France | Lauriane EBERST | Contact (sur clinicalTrials) | |||
| ICM Val d'Aurelle - 34298 - Montpellier - France | Stanislas QUESADA | Contact (sur clinicalTrials) | |||
| ICO Paul Papin - 49055 - Angers - France | Paule AUGEREAU | Contact (sur clinicalTrials) | |||
| ICONE - 51430 - Bezannes - France | Karinne PRULHIERE | Contact (sur clinicalTrials) | |||
| Institut Paoli Calmettes - 13009 - Marseille - France | Maria KFOURY | Contact (sur clinicalTrials) | |||
| Oncopole Claudius Regaud - IUCT Oncopole - 31059 - Toulouse - France | Sarah BETRIAN-LAGARDE | Contact (sur clinicalTrials) | |||
| Sainte Catherine - Institut du Cancer Avignon - 84918 - Avignon - France | Julien GRENIER | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- Patients having received at least one dose of lenvatinib plus pembrolizumab in the
context of the French early access program (Temporary Authorisation for Use)
approved by the French Health Autority.
- Patients with advanced or recurrent endometrial cancer whose disease is progressing
during or following prior platinum-based chemotherapy at any stage and who are not
eligible for curative surgery or radiotherapy, according to the French early access
program (Temporary Authorisation for Use) approved by the French Health Autority
criteria.
- Patients having received at least one dose of lenvatinib plus pembrolizumab in the
context of the French early access program (Temporary Authorisation for Use)
approved by the French Health Autority.
- Patients with advanced or recurrent endometrial cancer whose disease is progressing
during or following prior platinum-based chemotherapy at any stage and who are not
eligible for curative surgery or radiotherapy, according to the French early access
program (Temporary Authorisation for Use) approved by the French Health Autority
criteria.
- Patients who refuse the collection and use of their personal data in the course of
this research.